Articles tagged "Safety"

2018 American Transplant Congress
Safety and Efficacy of Real-World Use of Everolimus for Kidney Transplant Patients: Post-Marketing Surveillance in Japan
H. Harada,¹ Y. Watarai,² J. Uchida,³ O. Kamisawa.⁴
¹Sapporo City General Hospital, Sapporo, Japan; ²Nagoya Daini Red Cross Hospital, Nagaya, Japan; ³Osaka City University, Osaka, Japan; ⁴Novartis Pharma K.K., Tokyo, Japan.
Background and purpose: After the approval of everolimus (EVR) in 2011 in Japan to prevent organ rejection in kidney transplant (KTx) patients, no data on…
2018 American Transplant Congress
Excellent Outcomes for HCV-Viremic Recipients of Simultaneous Liver-Kidney Transplant in the Direct Anti-Viral Era
A. Ray, C. Klein, T. Ommert, R. Cross, R. Rubin.
Piedmont Transplant Institute, Piedmont Healthcare, Atlanta, GA.
Before the era of direct anti-viral agents (DAAs), outcomes for HCV-viremic recipients of simultaneous liver kidney transplant (SLKT) were inferior to HCV-negative recipients. PURPOSE: To…
2017 American Transplant Congress
Safety of Percutaneous Pancreas Allograft Biopsy in Enteric Drained Pancreas Transplants.
Y. Kassis, E. Poggio, Z. Zaky.
Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland, OH
Background: Pancreas allograft biopsy (Bx) is the gold standard in diagnosing allograft rejection. The safety of this procedure has been controversial, thus limiting its widespread…
2017 American Transplant Congress
Confirmation of the Safety of Cryopreserved Human Cord Blood Derived Di-Chimeric Cells in the NSG Mouse Model.
J. Cwykiel, N. Filipek, E. Szilagyi, E. Tfaily, M. Siemionow.
Orthopaedics, University of Illinois at Chicago, Chicago, IL
Background: Cell therapies are a promising approach for tolerance induction in Vascularized Composite Allotransplantation (VCA). Thus, we have developed a new supportive therapy of ex…
2017 American Transplant Congress
Alloimmune Quiescence in Recipients with Long-Term Surviving Kidney Grafts.
K. Brown,¹ W. Baldwin,¹ E. Poggio,² W. Braun,² R. Fairchild.¹
¹Department of Immunology, Cleveland Clinic, Cleveland, OH; ²Nephrology and Glickman Urological Institue, Cleveland Clinic, Cleveland, OH
Recent studies of tolerant kidney transplant patients have identified increased numbers of circulating B cells expressing an immature/transitional phenotype (IgD+CD27-/IgD+CD27-CD24+CD38+). Similar frequencies of these immature/transitional…
2017 American Transplant Congress
Efficacy and Safety of Everolimus with Reduced Tacrolimus or Cyclosporine in Pediatric Liver Transplant Recipients: 12-Month Results from H2305 Study.
A. Weymann,¹ R. Ganschow,¹ B. Ericzon,¹ A. Dhawan,¹ K. Sharif,¹ E.-D. Martzloff,² B. Rauer,² J. Ng,² P. Lopez.²
¹H2305 Study Group, St Louis; ²Novartis Pharma AG, Basel, Switzerland
Purpose: Everolimus (EVR) facilitated calcineurin inhibitor (CNI) reduction has shown improved renal function (RF) without compromising efficacy in adult liver transplant recipients (LTxR). Here we…
2017 American Transplant Congress
Effect of Everolimus-Based Immunosuppressive Regimen on New Onset of Diabetes After Kidney Transplantation – A 24 Month Subanalysis from the ELEVATE Study.
H. Holdaas,¹ S. Chadban,¹ J. de Fijter,¹ L. Rostaing,¹ U. Mancilla,¹ P. Lopez,² G. Bader,² J. Cruzado,¹ M. van der Giet.¹
¹ELEVATE Study Group, Oslo, Norway; ²Novartis Pharma AG, Basel, Switzerland
Purpose: New onset diabetes after transplantation (NODAT) is a common metabolic complication which affects long-term patient survival and graft outcomes. Most of the immunosuppressive drugs…
2017 American Transplant Congress
First Report of Human Liver Transplantation After Normothermic Machine Perfusion (NMP) in the United States.
Q. Liu, B. Soliman, G. Iuppa, A. Nassar, A. Hassan, T. Diago Uso, K. Hashimoto, F. Aucejo, M. Fujiki, B. Eghtesad, J. Cywinski, S. Irefin, J. Fung, K. Abu-Elmagd, C. Miller, C. Quintini.
Cleveland Clinic, Cleveland
NMP is a novel preservation method for liver grafts. We transplanted 10 human livers after NMP to test the safety and feasibility of NMP on…
2017 American Transplant Congress
We Wish This Would Never Happen Again! Implementation of an Adverse Event Review System to Improve the Safety of Pediatric Solid Organ Transplant (SOT) Patients.
J. Gossett,¹ M. Lake,¹ J. Bucuvalas,² A. Basu,¹ L. Burkhart,¹ L. Danziger-Isakov,¹ A. Lorts.¹
¹Solid Organ Transplant Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; ²Division of Gastroenterology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background: 50% of SOT centers are cited by CMS for inadequate review of adverse events (AE)s. AE reviews are inconsistently performed, rarely cover near misses…
2017 American Transplant Congress
IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).
S. Ge, B.-H. Shin, J. Mirocha, D. Thomas, M. Chu, E. Rodriguez, C. Chao, A. Petrosyan, O. Galera, A. Vo, J. Choi, A. Peng, J. Kahwaji, S. Jordan, M. Toyoda.
Transplant Immunology Laboratory, Biostatistics Core and Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
Background: VIs represent significant morbidity factors in KTx pts. DES followed by KTx with ATZ induction increased successful Tx rates in HS pts, but may…